Similar articles

• Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors.

  Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, Shields JA. Shields CL, et al. Am J Ophthalmol. 2004 Sep;138(3):329-37. doi: 10.1016/j.ajo.2004.04.032. Am J Ophthalmol. 2004. PMID: 15364213 Clinical Trial.
• The International Classification of Retinoblastoma predicts chemoreduction success.

  Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT, Shields JA. Shields CL, et al. Ophthalmology. 2006 Dec;113(12):2276-80. doi: 10.1016/j.ophtha.2006.06.018. Epub 2006 Sep 25. Ophthalmology. 2006. PMID: 16996605
• Retinocytoma shows lack of response to chemoreduction.

  Chung J, Turaka K, Shields CL. Chung J, et al. J Pediatr Ophthalmol Strabismus. 2010 Dec 22;47 Online:e1-3. doi: 10.3928/01913913-20101217-03. J Pediatr Ophthalmol Strabismus. 2010. PMID: 21175116
• Chemotherapy for retinoblastoma.

  Chan HS, Gallie BL, Munier FL, Beck Popovic M. Chan HS, et al. Ophthalmol Clin North Am. 2005 Mar;18(1):55-63, viii. doi: 10.1016/j.ohc.2004.11.002. Ophthalmol Clin North Am. 2005. PMID: 15763191 Review.
• Overview: chemotherapy for retinoblastoma: an expanding area of clinical research.

  Schouten-Van Meeteren AY, Moll AC, Imhof SM, Veerman AJ. Schouten-Van Meeteren AY, et al. Med Pediatr Oncol. 2002 Jun;38(6):428-38. doi: 10.1002/mpo.1358. Med Pediatr Oncol. 2002. PMID: 11984806 Review. No abstract available.